Skip to main content
Prof. Dr. Marieta Toma
Johann Saba, UKB

News categories: Focus

Welcoming Marieta Toma to ImmunoSensation

We are thrilled to welcome Prof. Dr. Marieta Toma Deputy Director of the Institute of Pathology at the University Hospital Bonn as a new member of the ImmunoSensation2 Cluster of Excellence. Marieta Toma is a leading expert in translational research with particular interest in establishing patient-derived models for cancer research.

Research focus: From patient-derived primary cell lines to organoids

The working group of Marieta Toma employs patient-derived primary cell models and organoid systems, that are used to study the complex biology of solid malignant tumors. Marieta Toma’s research focuses on establishing applicable models and identifying disease biomarkers for cancer research. Her expertise ranges from a variety of diseases, with particular interest kidney tumors, bile duct carcinomas, and brain metastases.

A key aspect of Marieta Toma’s work involves developing patient-derived models that closely mimic the tumor microenvironment. These advanced systems allow researchers to investigate the molecular mechanisms that influence disease development and progression. In addition, Marieta Toma’s group uses advanced techniques such as microscopy, pathologic diagnostics, spatial biology, and image analysis tools to uncover the complex interplay between different environmental factors that impact tumor development. 

Collaborations within the Cluster

Marieta Toma’s collaboration with the ImmunoSensation2 scientists offers the potential to integrate advanced immunological profiling with her state-of-the-art organoid models, paving the way for impactful discoveries.

Looking ahead

In the future, Marieta Toma aims to further unravel the immunological dynamics within solid tumors. Her future research will explore how the complex interactions within tissue influence tumor progression and resistance to therapy, ultimately aiming to improve therapeutic outcomes for patients with aggressive cancers.

Marieta Toma shares her enthusiasm for joining the Cluster: “The integration of patient-derived models with immunological research offers unprecedented opportunities to bridge the gap between basic science and clinical application. I am excited to contribute to ImmunoSensation2’s efforts to better understand and treat immune-related diseases.”

We warmly welcome Marieta Toma to ImmunoSensation and are excited about the innovative contributions she will bring to our Cluster.

 

Contact:

Prof. Dr. Marieta Toma

Institute of Pathology

University Hospital Bonn

Email: marieta.toma@ukbonn.de 

Related news

members of the Bonn-Cumming Host-Directed Pandemic Therapeutics Program

News categories: Focus

Joining forces against future pandemics

Three days of scientific exchange, workshops, and new impulses: Until July 2, 2025, members of the Bonn-Cumming Host-Directed Pandemic Therapeutics Program are gathered at University Hospital Bonn (UKB) for a symposium to reflect on the current state of their research and discuss further steps. The joint program of the Cumming Global Centre for Pandemic Therapeutics at the University of Melbourne and of the University of Bonn aims to combat future pandemics with novel therapeutics.
View entry
Prof. Dr. Jörg Wenzel

News categories: Focus

Welcoming Jörg Wenzel to ImmunoSensation

We are delighted to welcome Prof. Dr. Jörg Wenzel from the Center for Skin Diseases at the University Hospital Bonn to the Cluster of Excellence ImmunoSensation2. Jörg Wenzel is a dermatologist and physician-scientist with extensive expertise in inflammatory skin diseases and cutaneous immunology.
View entry
Prof. Dr. Christian Bode

News categories: Focus

Welcoming Christian Bode to ImmunoSensation

We are delighted to welcome Prof. Dr. Christian Bode from the Department of Anesthesiology and Intensive Care Medicine at the University Hospital Bonn to the Cluster of Excellence ImmunoSensation2. Christian Bode is a physician-scientist whose work focuses on the intersection of immunology and critical care. His research centers around understanding the immune responses in patients undergoing major surgery, acute lung failure (ARDS), or sepsis.
View entry

Back to the news overview